VivoSeq
Other

Dentin Hypersensitivity

0

Pipeline Programs

3

Active Trials

1

Companies Involved

Dentin Hypersensitivity is an early-stage landscape with 0 programs across 1 company. The most active players are GSK.

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

95/100

Attrition Rate

4/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

28

clinical trials

Completed19 · 68%
Unknown status5 · 18%
Recruiting2 · 7%
Withdrawn1 · 4%
Not yet recruiting1 · 4%

Trial Activity

28 trials

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)